Clinical trials: sponsored by Zhejiang Cancer Hospital
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer, PDL1 Gene Mutation
Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.
The goal of this clinical trial is to observe the efficacy and safety of Serplulimab monotherapy as a neoadjuvant treatment for TPS ≥ 50% non-small cell lung cancer (NSCLC).
- Trial name
- NSCLC (NCT06195683)
- Testing
- Serplulimab
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Zhejiang Cancer Hospital
CRC, Metastatic Colorectal Cancer
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
The aim of this study is to evaluate the efficacy and safety of short course radiotherapy followed by fruquintinib combined with Sintilimab as the first-line treatment of advanced mCRC compared to bevacizumab combined with…
- Conditions
- CRC, Metastatic Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT06195670
- Testing
- Experimental, Active Comparator
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Squamous Cell Carcinoma
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
The goal of this clinical trial is to evaluate the efficacy and safety of sintilimab as adjuvant therapy in node-positive esophageal squamous cell carcinoma after radical surgery without neoadjuvant therapy.
- Trial name
- NCT06190639
- Testing
- sintilimab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang Cancer Hospital
Pathological Conditions, Signs and Symptoms
PTC Guiding Neoadjuvant Treatment in Breast Cancer
Patients with breast cancer meet criteria for enrollment are randomized into PTC group or control group. The neoadjuvant therapy regimens are guided by PTC test in the PTC group.
- Trial name
- NCT05103293
- Testing
- patient-derived tumor-like cell clusters drug sensitivity test
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Zhejiang Cancer Hospital
Liver Cancer, Ciprofol
Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation
Efficacy and Safety of Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation
- Trial name
- NCT06178926
- Testing
- Propofol, Ciprofol
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Cancer Hospital
Small Cell Lung Cancer Limited Stage
PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients
At present, prophylactic cranial irradiation (PCI) is part of standard care for patients with limited-stage small cell lung cancer (SCLC) who have achieved good response after definitive thoracic radiotherapy and chemotherapy.
- Trial name
- NCT05651802
- Testing
- Prophylactic cranial irradiation, Thoracic radiotherapy, Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 220 people
- Sponsor
- Zhejiang Cancer Hospital
Hypoxia
The 90% Effective Flow of High Flow Nasal Oxygenation (HFNO) During Sedated Bronchoscopy
Patients undergoing sedated bronchoscopy were randomized into six groups (10 Liters/minute [L/min], 20 L/min, 30 L/min, 40 L/min, 50 L/min, 60 L/min). The primary outcome was the incidence of hypoxemia.
- Trial name
- HFNO (NCT05298319)
- Testing
- high flow nasal cannula
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block for Breast Cancer Surgery
This is a prospective, randomized, controlled trial for evaluating the efficacy of addition of transversus thoracic muscle plane block to pectoral nerves block versus pectoral nerves block for quality of recovery scores in breast…
- Trial name
- NCT05448638
- Testing
- the combination of transversus thoracic muscle plane and pectoral nerves blocks, the pectoral nerves block only
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Neoplasms
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
The treatment regimen of lenvatinib combined with PD1 antibody has brought earth shaking changes to the immunotherapy of various "cold tumors".
- Trial name
- NCT06140576
- Testing
- Sindilimab, Nab-paclitaxel, Lenvatinib
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer, Multi-omics
A Multi-omics-based Metabolic Typing Study of Gastric Cancer
In the study, the investigators obtained gastric cancer tissues from 480 gastric cancer patients who had undergone surgery at the Zhejiang Cancer Hospital's biospecimen bank between 2012-2019, and obtained relevant clinical…
- Conditions
- Gastric Cancer, Multi-omics, Diagnosis
- Trial name
- NCT06134011
- Testing
- Without any intervention
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.
This is a single-arm, Phase II clinical study to explore the efficacy and safety of dalpiciclib combined with fluvestrant and compound gossypol acetate tablets in advanced HR-positive and HER2-negative breast cancer after CDK4/6…
- Trial name
- NCT06133088
- Testing
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Zhejiang Cancer Hospital
Ovarian Neoplasm Epithelial
The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological Surgery
Primary cytoreductive surgery for ovarian cancer is an ideal setting to evaluate endothelial function under ANH and AHH, as the procedure is associated with moderately high blood loss.
- Trial name
- NCT06103214
- Testing
- acute normovolemic hemodilution (ANH), acute hypervolemic hemodilution (AHH)
- Volunteers
- 144 people
- Sponsor
- Zhejiang Cancer Hospital
Bile Duct Adenocarcinoma
Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma
This is an open-label, single-arm, multicenter Phase II clinical study to evaluate the efficacy and safety of surufatinib combined with cardanilimab in second-line treatment of patients with inoperable or metastatic bile duct…
- Trial name
- NCT06092645
- Testing
- surufatinib plus cadonilimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Cancer Hospital
Diffuse Large B Cell Lymphoma
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy.
- Trial name
- NCT05290090
- Testing
- Rituximab, Lenalidomide, Zanubrutinib and RCHOP
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang Cancer Hospital
Lung Cancer, Small Cell
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of tislelizumab combined with sitravatinib as maintenance therapy following tislelizumab and chemotherapy for treatment naïve…
- Trial name
- NCT05228496
- Testing
- Tislelizumab, Sitravatinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhejiang Cancer Hospital
Biliary Tract Tumor, Cholangiocarcinoma
Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy
A prospective, observational study to explore multidimensional biomarkers for predicting the efficacy of immunotherapy In biliary tract tumors
- Trial name
- NCT06048289
- Testing
- Blood samples, tumor biopsy specimens will be collected
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang Cancer Hospital
Glioblastoma
Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma
The purpose of this study is to test the the efficacy and safety of Anlotinib in combination with STUPP regimen for patients with newly diagnosed glioblastoma.
- Trial name
- NCT04119674
- Testing
- Drug is Anlotinib., Drug is Temozolomide Capsule., Radiotherapy was initiated 4 to 6 weeks postoperatively.
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Zhejiang Cancer Hospital
Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Patients with newly diagnosed MCL were treated with ZR2 regimen for 3 cycles, followed by 3 cycles of immunochemotherapy, and zebrutinib maintenance therapy for 2 years after the end of induction therapy, in order to improve the…
- Trial name
- NCT05992597
- Testing
- ZR2 RDHAP
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer, Peritoneal Metastases
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
To evaluate the efficacy and safety of Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion as First-line Treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma…
- Conditions
- Gastric Cancer, Peritoneal Metastases, Ascites, Malignant
- Trial name
- NCT06046963
- Testing
- Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion, Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital